|

LP-118 Clinical Trials

2 actively recruiting trials across 1 location

Pipeline

Phase 1: 1Phase 1/2: 1

Top Sponsors

  • University of Chicago1
  • Newave Pharmaceutical Inc1

Indications

  • Cancer2
  • Myelodysplastic Neoplasm in Blast Phase1
  • Myeodysplastic Syndrome1
  • T-cell Prolymphocytic Leukemia1
  • Lymphoblastic Leukemia1

Chicago, Illinois2 trials

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

University of Chicago Medicine Comprehensive Cancer Center

Phase 1/2
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

University of Chicago

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.